SARS-CoV-2 antigen and influenza A + B combined rapid test

The COVID-19 Combined Rapid COVID-19 and Influenza A+B Antigen Test is a lateral flow immunoassay for the qualitative detection of nucleoprotein antigens of SARS-CoV-2, Influenza A and Influenza B viruses in the nasopharynx.

Category:
Send request

To find out more about the product - fill in the form and we will contact you.

Perskaičiau ir sutinku su taisyklėmis nurodytomis privacy policy

Symptoms of SARS-CoV-2 and influenza viral respiratory infections can be similar. The COVID-19 Combined Rapid COVID-19 and Influenza A+B Antigen Test is designed to detect and distinguish between the nucleoprotein antigens of SARS-CoV-2, influenza A and B viruses. Antigens are usually detected from nasopharyngeal samples during the acute phase of infection. Positive results indicate the presence of viral antigens, but correlation with the patient's history and other diagnostic information is necessary to establish infection. Positive results do not exclude bacterial infection or other concomitant viral infection. Negative results do not exclude SARS-CoV-2, influenza type A or influenza infection, and therefore decisions on patient treatment or care, including infection control, should not be based on this test alone. Negative results should be combined with clinical signs, patient history and epidemiological information, and confirmed by molecular testing if necessary for the treatment of the patient. The combined rapid test for COVID-19 and influenza A+B antigens must be used by qualified clinical laboratory personnel trained in in vitro diagnostic procedures.

The COVID-19 and Influenza A+B Antigen Combined Rapid Test is a qualitative lateral flow immunoassay for the detection of SARS-CoV-2, Influenza A and Influenza B nucleoprotein N protein in a nasopharyngeal swab. In this test, antibodies specific for SARS-CoV-2, influenza A and B nucleoprotein N protein are separately attached to the test cartridge lines. During the test, the extracted sample reacts with antibodies against SARS-CoV-2, influenza A and/or influenza B nucleoprotein N protein coated on the test particle. The mixture migrates across the membrane, reacts with antibodies to SARS-CoV-2, influenza A and/or B type N protein on the membrane and a single coloured line appears in the test area. The appearance of this coloured line in the test area indicates a positive result. The test has an internal control, so that a coloured line will always appear in the control area when the test is performed correctly.

Scroll to Top